Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer.

Kim RD, McDonough S, El-Khoueiry AB, Bekaii-Saab TS, Stein SM, Sahai V, Keogh GP, Kim EJ, Baron AD, Siegel AB, Barzi A, Guthrie KA, Javle M, Hochster H.

Eur J Cancer. 2020 Mar 29;130:219-227. doi: 10.1016/j.ejca.2020.01.026. [Epub ahead of print]

PMID:
32234665
2.

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.

Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, Paulson AS, Borad MJ, Gallinson D, Murphy AG, Oh DY, Dotan E, Catenacci DV, Van Cutsem E, Ji T, Lihou CF, Zhen H, Féliz L, Vogel A.

Lancet Oncol. 2020 Mar 20. pii: S1470-2045(20)30109-1. doi: 10.1016/S1470-2045(20)30109-1. [Epub ahead of print]

PMID:
32203698
3.

Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial.

Pishvaian MJ, Blais EM, Brody JR, Lyons E, DeArbeloa P, Hendifar A, Mikhail S, Chung V, Sahai V, Sohal DPS, Bellakbira S, Thach D, Rahib L, Madhavan S, Matrisian LM, Petricoin EF 3rd.

Lancet Oncol. 2020 Apr;21(4):508-518. doi: 10.1016/S1470-2045(20)30074-7. Epub 2020 Mar 2. Erratum in: Lancet Oncol. 2020 Apr;21(4):e182.

PMID:
32135080
4.

Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation.

O'Reilly EM, Lee JW, Zalupski M, Capanu M, Park J, Golan T, Tahover E, Lowery MA, Chou JF, Sahai V, Brenner R, Kindler HL, Yu KH, Zervoudakis A, Vemuri S, Stadler ZK, Do RKG, Dhani N, Chen AP, Kelsen DP.

J Clin Oncol. 2020 Jan 24:JCO1902931. doi: 10.1200/JCO.19.02931. [Epub ahead of print]

PMID:
31976786
5.

Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers.

Mizrahi JD, Gunchick V, Mody K, Xiao L, Surapaneni P, Shroff RT, Sahai V.

World J Gastrointest Oncol. 2020 Jan 15;12(1):83-91. doi: 10.4251/wjgo.v12.i1.83.

6.

Quantitative Imaging Assessment for Clinical Trials in Oncology.

Hersberger KE, Mendiratta-Lala M, Fischer R, Kaza RK, Francis IR, Olszewski MS, Harju JF, Shi W, Manion FJ, Al-Hawary MM, Sahai V.

J Natl Compr Canc Netw. 2019 Dec;17(12):1505-1511. doi: 10.6004/jnccn.2019.7331.

PMID:
31805530
7.

A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Patients with Metastatic Pancreatic Cancer.

Sahai V, Saif MW, Kalyan A, Philip PA, Rocha-Lima CM, Ocean A, Ondovik MS, Simeone DM, Banerjee S, Bhore R, Louis CU, Picozzi V.

J Pancreat Cancer. 2019 Sep 25;5(1):35-42. doi: 10.1089/pancan.2019.0012. eCollection 2019.

8.

Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer.

Tran NH, Sahai V, Griffith KA, Nathan H, Kaza R, Cuneo KC, Shi J, Kim E, Sonnenday CJ, Cho CS, Lawrence TS, Zalupski MM.

Int J Radiat Oncol Biol Phys. 2020 Jan 1;106(1):124-133. doi: 10.1016/j.ijrobp.2019.08.057. Epub 2019 Sep 5.

PMID:
31494181
9.

Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer.

Cuneo KC, Morgan MA, Sahai V, Schipper MJ, Parsels LA, Parsels JD, Devasia T, Al-Hawaray M, Cho CS, Nathan H, Maybaum J, Zalupski MM, Lawrence TS.

J Clin Oncol. 2019 Oct 10;37(29):2643-2650. doi: 10.1200/JCO.19.00730. Epub 2019 Aug 9.

10.

Role of pelvic CT during surveillance of patients with resected biliary tract cancer.

Aslam A, Mendiratta-Lala M, Curci NE, Gunchick V, Hersberger KE, Bilal A, Francis IR, Sahai V.

Abdom Radiol (NY). 2020 Jan;45(1):116-122. doi: 10.1007/s00261-019-02159-0.

PMID:
31385009
11.

A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer.

Hu ZI, Bendell JC, Bullock A, LoConte NK, Hatoum H, Ritch P, Hool H, Leach JW, Sanchez J, Sohal DPS, Strickler J, Patel R, Wang-Gillam A, Firdaus I, Yu KH, Kapoun AM, Holmgren E, Zhou L, Dupont J, Picozzi V, Sahai V, O'Reilly EM.

Cancer Med. 2019 Sep;8(11):5148-5157. doi: 10.1002/cam4.2425. Epub 2019 Jul 26.

12.

Guidelines Insights: Hepatobiliary Cancers, Version 2.2019.

Benson AB, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Anaya DA, Anders R, Are C, Brown D, Chang DT, Cloyd J, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Hammond LJ, Darlow SD.

J Natl Compr Canc Netw. 2019 Apr 1;17(4):302-310. doi: 10.6004/jnccn.2019.0019.

PMID:
30959462
13.

Pilot Study of Personalized Video Visit Summaries for Patients With Cancer.

Krauss JC, Sahai V, Kirch M, Simeone DM, An L.

JCO Clin Cancer Inform. 2018 Dec;2:1-8. doi: 10.1200/CCI.17.00086.

14.

Predictors of immunotherapy-induced immune-related adverse events.

Kartolo A, Sattar J, Sahai V, Baetz T, Lakoff JM.

Curr Oncol. 2018 Oct;25(5):e403-e410. doi: 10.3747/co.25.4047. Epub 2018 Oct 31.

15.

A Radiologist's Guide to Response Evaluation Criteria in Solid Tumors.

Lalchandani UR, Sahai V, Hersberger K, Francis IR, Wasnik AP.

Curr Probl Diagn Radiol. 2019 Nov - Dec;48(6):576-585. doi: 10.1067/j.cpradiol.2018.07.016. Epub 2018 Aug 2. Review.

PMID:
30181058
16.

Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.

Sahai V, Catalano PJ, Zalupski MM, Lubner SJ, Menge MR, Nimeiri HS, Munshi HG, Benson AB 3rd, O'Dwyer PJ.

JAMA Oncol. 2018 Dec 1;4(12):1707-1712. doi: 10.1001/jamaoncol.2018.3277.

17.

Open-label, multicenter, single-arm study of FABLOx (metronomic 5-fluorouracil plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin) in patients with metastatic pancreatic cancer: Phase I results.

Sahai V, Saif W, Kalyan A, Philip P, Rocha-Lima C, Ocean A, Ondovik M, Simeone D, Karnoub M, Louis C, Picozzi V.

Ann Oncol. 2018 Jun;29 Suppl 5:v43. doi: 10.1093/annonc/mdy151.154. Epub 2020 Jan 7. No abstract available.

18.

Irinotecan-associated dysarthria: A single institution case series with management implications in patients with gastrointestinal malignancies.

Zhen DB, McDevitt RL, Zalupski MM, Sahai V.

J Oncol Pharm Pract. 2019 Jun;25(4):980-986. doi: 10.1177/1078155218763044. Epub 2018 Mar 21.

PMID:
29562843
19.

Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies.

Hurwitz H, Van Cutsem E, Bendell J, Hidalgo M, Li CP, Salvo MG, Macarulla T, Sahai V, Sama A, Greeno E, Yu KH, Verslype C, Dawkins F, Walker C, Clark J, O'Reilly EM.

Invest New Drugs. 2018 Aug;36(4):683-695. doi: 10.1007/s10637-018-0580-2. Epub 2018 Mar 6.

20.

Bone marrow edema associated with everolimus.

McDevitt RL, Quinlan C, Hersberger K, Sahai V.

Am J Health Syst Pharm. 2018 Jan 1;75(1):e23-e27. doi: 10.2146/ajhp170269.

PMID:
29273609
21.

Defining and Using Preoperative Predictors of Diabetic Remission Following Bariatric Surgery.

Stallard R, Sahai V, Drover JW, Chun S, Keresztes C.

JPEN J Parenter Enteral Nutr. 2018 Mar;42(3):573-580. doi: 10.1177/0148607117697934. Epub 2017 Dec 12.

PMID:
29187047
22.

High-Throughput Microfluidic Labyrinth for the Label-free Isolation of Circulating Tumor Cells.

Lin E, Rivera-Báez L, Fouladdel S, Yoon HJ, Guthrie S, Wieger J, Deol Y, Keller E, Sahai V, Simeone DM, Burness ML, Azizi E, Wicha MS, Nagrath S.

Cell Syst. 2017 Sep 27;5(3):295-304.e4. doi: 10.1016/j.cels.2017.08.012. Epub 2017 Sep 20.

23.

ATM-deficiency increases genomic instability and metastatic potential in a mouse model of pancreatic cancer.

Drosos Y, Escobar D, Chiang MY, Roys K, Valentine V, Valentine MB, Rehg JE, Sahai V, Begley LA, Ye J, Paul L, McKinnon PJ, Sosa-Pineda B.

Sci Rep. 2017 Sep 11;7(1):11144. doi: 10.1038/s41598-017-11661-8.

24.

A phase 1/2 study of metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer.

Picozzi V, Sahai V, Simeone D, Rocha Lima C, Ocean A, Philip P, Saif W, Kalyan A, Ondovik M, Shiansong Li J, Louis C.

Ann Oncol. 2017 Jun;28 Suppl 3:iii81-iii82. doi: 10.1093/annonc/mdx261.229. No abstract available.

25.

NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017.

Benson AB 3rd, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Zhu AX, Hoffmann KG, Darlow S.

J Natl Compr Canc Netw. 2017 May;15(5):563-573.

26.

Value of pelvis CT during follow-up of patients with pancreatic adenocarcinoma.

Bailey JJ, Ellis JH, Davenport MS, Cohan RH, Nan B, Parameswaran A, Hsu L, Sahai V, Francis IR.

Abdom Radiol (NY). 2017 Jan;42(1):211-215. doi: 10.1007/s00261-016-0869-6.

27.

A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer.

Zhen DB, Griffith KA, Ruch JM, Camphausen K, Savage JE, Kim EJ, Sahai V, Simeone DM, Zalupski MM.

Invest New Drugs. 2016 Dec;34(6):733-739. Epub 2016 Jul 21.

PMID:
27439894
28.

Opportunities and Challenges for Pancreatic Circulating Tumor Cells.

Nagrath S, Jack RM, Sahai V, Simeone DM.

Gastroenterology. 2016 Sep;151(3):412-26. doi: 10.1053/j.gastro.2016.05.052. Epub 2016 Jun 20. Review.

PMID:
27339829
29.

Targeting BET bromodomain proteins in solid tumors.

Sahai V, Redig AJ, Collier KA, Eckerdt FD, Munshi HG.

Oncotarget. 2016 Aug 16;7(33):53997-54009. doi: 10.18632/oncotarget.9804. Review.

30.

GM-CSF Mediates Mesenchymal-Epithelial Cross-talk in Pancreatic Cancer.

Waghray M, Yalamanchili M, Dziubinski M, Zeinali M, Erkkinen M, Yang H, Schradle KA, Urs S, Pasca Di Magliano M, Welling TH, Palmbos PL, Abel EV, Sahai V, Nagrath S, Wang L, Simeone DM.

Cancer Discov. 2016 Aug;6(8):886-99. doi: 10.1158/2159-8290.CD-15-0947. Epub 2016 May 16.

31.

Hand hygiene and health care hierarchy by year of medical education.

Sahai V, Eden K, Glustein S.

Educ Health (Abingdon). 2015 May-Aug;28(2):148-9. doi: 10.4103/1357-6283.170120. No abstract available.

32.

Expression and Control of Codon-Optimized Granulocyte Colony-Stimulating Factor in Pichia pastoris.

Maity N, Thawani A, Sharma A, Gautam A, Mishra S, Sahai V.

Appl Biochem Biotechnol. 2016 Jan;178(1):159-72. doi: 10.1007/s12010-015-1865-y. Epub 2015 Sep 26.

PMID:
26410223
33.

Hand hygiene and health care hierarchy: A resident's perspective.

Sahai V, Eden K, Glustein S.

Educ Health (Abingdon). 2014 Sep-Dec;27(3):297-8. doi: 10.4103/1357-6283.152195. No abstract available.

34.

Incidents resulting from staff leaving normal duties to attend medical emergency team calls.

Concord Medical Emergency Team (MET) Incidents Study Investigators, Cheung W, Sahai V, Mann-Farrar J, Skylas K, Uy J, Doyle B.

Med J Aust. 2014 Nov 3;201(9):528-31.

PMID:
25358577
35.

Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma.

Kim EJ, Sahai V, Abel EV, Griffith KA, Greenson JK, Takebe N, Khan GN, Blau JL, Craig R, Balis UG, Zalupski MM, Simeone DM.

Clin Cancer Res. 2014 Dec 1;20(23):5937-5945. doi: 10.1158/1078-0432.CCR-14-1269. Epub 2014 Oct 2.

36.

Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study.

Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, Rademaker AW, Kulke MH.

Oncologist. 2014 Sep;19(9):930-6. doi: 10.1634/theoncologist.2014-0120. Epub 2014 Aug 5.

37.

Snail cooperates with Kras G12D in vivo to increase stem cell factor and enhance mast cell infiltration.

Knab LM, Ebine K, Chow CR, Raza SS, Sahai V, Patel AP, Kumar K, Bentrem DJ, Grippo PJ, Munshi HG.

Mol Cancer Res. 2014 Oct;12(10):1440-8. doi: 10.1158/1541-7786.MCR-14-0111. Epub 2014 Jun 18.

38.

Production of cellobiose dehydrogenase from a newly isolated white rot fungus Termitomyces sp. OE147.

Gupta G, Gangwar R, Gautam A, Kumar L, Dhariwal A, Sahai V, Mishra S.

Appl Biochem Biotechnol. 2014 Aug;173(8):2099-115. doi: 10.1007/s12010-014-1010-3. Epub 2014 Jun 15.

PMID:
24929309
39.

BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen.

Sahai V, Kumar K, Knab LM, Chow CR, Raza SS, Bentrem DJ, Ebine K, Munshi HG.

Mol Cancer Ther. 2014 Jul;13(7):1907-17. doi: 10.1158/1535-7163.MCT-13-0925. Epub 2014 May 7.

40.

Snail cooperates with KrasG12D to promote pancreatic fibrosis.

Shields MA, Ebine K, Sahai V, Kumar K, Siddiqui K, Hwang RF, Grippo PJ, Munshi HG.

Mol Cancer Res. 2013 Sep;11(9):1078-87. doi: 10.1158/1541-7786.MCR-12-0637. Epub 2013 Jun 12.

41.

Three-dimensional collagen I promotes gemcitabine resistance in vitro in pancreatic cancer cells through HMGA2-dependent histone acetyltransferase expression.

Dangi-Garimella S, Sahai V, Ebine K, Kumar K, Munshi HG.

PLoS One. 2013 May 16;8(5):e64566. doi: 10.1371/journal.pone.0064566. Print 2013.

42.

2011 update in gastrointestinal cancer therapeutics.

Sahai V, Nimeiri H, Benson AB 3rd.

Gastrointest Cancer Res. 2012 Jul;5(4 Suppl 2):S2-8.

43.

Effect of formulated root endophytic fungus Piriformospora indica and plant growth promoting rhizobacteria fluorescent pseudomonads R62 and R81 on Vigna mungo.

Kumar V, Sarma MV, Saharan K, Srivastava R, Kumar L, Sahai V, Bisaria VS, Sharma AK.

World J Microbiol Biotechnol. 2012 Feb;28(2):595-603. doi: 10.1007/s11274-011-0852-x. Epub 2011 Jul 28.

PMID:
22806855
44.

Loss of heterozygosity, aberrant methylation, BRAF mutation and KRAS mutation in colorectal signet ring cell carcinoma.

Kakar S, Deng G, Smyrk TC, Cun L, Sahai V, Kim YS.

Mod Pathol. 2012 Jul;25(7):1040-7. doi: 10.1038/modpathol.2012.44. Epub 2012 Apr 20.

45.

Shelf-life enhancement of bio-inoculant formulation by optimizing the trace metals ions in the culture medium for production of DAPG using fluorescent pseudomonad R62.

Saharan K, Sarma MV, Prakash A, Johri BN, Bisaria VS, Sahai V.

Enzyme Microb Technol. 2011 Jan 5;48(1):33-8. doi: 10.1016/j.enzmictec.2010.09.002. Epub 2010 Sep 15.

PMID:
22112768
46.

Allograft closure of lateral release after revision total knee arthroplasty.

Sahai V, Bono JV, Talmo CT.

J Arthroplasty. 2012 Mar;27(3):494.e9-12. doi: 10.1016/j.arth.2011.06.006. Epub 2011 Aug 9.

PMID:
21831578
47.

Using web search query data to monitor dengue epidemics: a new model for neglected tropical disease surveillance.

Chan EH, Sahai V, Conrad C, Brownstein JS.

PLoS Negl Trop Dis. 2011 May;5(5):e1206. doi: 10.1371/journal.pntd.0001206. Epub 2011 May 31.

48.

Application of inorganic carrier-based formulations of fluorescent pseudomonads and Piriformospora indica on tomato plants and evaluation of their efficacy.

Sarma MV, Kumar V, Saharan K, Srivastava R, Sharma AK, Prakash A, Sahai V, Bisaria VS.

J Appl Microbiol. 2011 Aug;111(2):456-66. doi: 10.1111/j.1365-2672.2011.05062.x. Epub 2011 Jun 21.

49.

High-density spore production of Piriformospora indica, a plant growth-promoting endophyte, by optimization of nutritional and cultural parameters.

Kumar V, Sahai V, Bisaria VS.

Bioresour Technol. 2011 Feb;102(3):3169-75. doi: 10.1016/j.biortech.2010.10.116. Epub 2010 Oct 30.

PMID:
21095631
50.

Bioprocess strategies for enhanced production of xylanase by Melanocarpus albomyces IITD3A on agro-residual extract.

Biswas R, Sahai V, Mishra S, Bisaria VS.

J Biosci Bioeng. 2010 Dec;110(6):702-8. doi: 10.1016/j.jbiosc.2010.07.013. Epub 2010 Aug 17.

PMID:
20724213

Supplemental Content

Support Center